
### Pharmaceutical Sales Force of the Future

How the role of the Pharma Sales Representative changes towards providing insights instead of information and how the interaction with the Healthcare Professional (HCP) intensifies for individual steps of the HCP journey.

The Pharmaceutical industry continues to experience shifts from managing diseases to managing patients' health, from payment for drugs to payment for outcomes, from one-drug-fits-all to precision medicine – in short: The Pharma industry continues to become more patient-centric.

These **developments** offer the potential for Pharma companies to **disrupt** current **business models** and achieve functional excellence. As important component of Pharma companies, the Marketing & Sales function will also be affected. On the following pages, we would like to share our thinking regarding how the above-mentioned developments impact the Marketing & Sales function and more specifically shape the future Pharmaceutical Sales Force.

#### The role of the Sales Force will change as information is easily available and willingness to see Sales Reps decreases



Insights

- Accessibility of HCPs decreases as HCPs increasingly obtain information online
- The Sales Force of the future will need to provide more than just information to increase HCP's willingness to see Sales Reps
- The current role of the Sales Force needs to progress


1) Extrapolated using previous years' growth rate Source Year: 2017 & 2015, US focus

### The HCP journey consists of the following steps

Awareness	0	Understand that current treatment is not optimal for the patient	Along the journey, pharmaceutical companies engage the HCP across multiple channels.
Recognition	0	Understand that treatment alternatives exist	For example, the <b>HCP</b> could <b>come</b> to the <b>awareness</b> that the <b>current treatment</b> option is not <b>ideal</b> by <b>accessing clinical trial</b>
Reflection	0	Comparing new treatment with other options/ products	results on the pharma <b>company's website</b> . Following that awareness, the <b>HCP could</b> <b>deepen</b> his/her <b>understanding</b> of treatment
Action	0	Prescribe new drug to patient and monitor treatment	alternatives by attending a Key Opinion Leader talk. During the Acceptance step the
Acceptance	0	Recommend drug to colleagues	<b>recommendation</b> to colleagues could occur via the online HCP <b>network platform</b> supplied by the pharma company.

# Sales Reps will need to provide insights instead of information; insight interpretation requires upskilling

Interaction intensity between the Sales Rep and the Healthcare Professional (HCP)



- HCPs will continue to increase the use of other data sources than sales reps to obtain drug related information reducing interaction intensity for recognition
- Increasing interaction intensity for action step as reps will provide insights based on
  - Individual patient data generated by remote monitoring devices (e.g. drug adherence)
  - Other patients' information and real world evidence (e.g. interference with newly approved drugs)
- Insight interpretation requires upskilling of Sales Reps

# Sales Reps require personalized information at the right time to satisfy changing HCP requirements

	Present	Near-term	Long-term
Material	<ul> <li>Deliver product information based on Marketing templates</li> </ul>	<ul> <li>Deliver insights based on real word evidence data</li> </ul>	<ul> <li>Deliver insights and recommendations based on physician's patients real-time, real-world data (e.g. adherence)</li> </ul>
Segmen- tation	<ul> <li>Based on subscription rate/ recommendation likeliness</li> </ul>	<ul> <li>Based on multiple factors (subscription rate, affiliations, publications,)</li> </ul>	<ul> <li>Based on multiple factors enriched with insights derived from patient-level data</li> </ul>
<mark>Channels</mark>	<ul> <li>Few utilized channels (e.g. Physician forums,) and not coordinated</li> </ul>	<ul> <li>Few but coordinated</li> </ul>	<ul> <li>Many and coordinated, complement otherwise already accessed information</li> </ul>

Increased Smart Data usage

In conclusion, we believe that the Pharmaceutical Sales Force will continue to exist but interaction with the Healthcare Professional (HCP) will change. Instead of creating awareness about the individual company's products and their benefits, the Sales Representative will provide insights and thereby interact more intensively with the HCP. This means that interaction intensity decreases during earlier steps of the HCP journey and increases for the action step.

In the long-term, we foresee that the **Sales Representative provides the HCP with patient insights based on real-world data**. For example, the Sales Representative could provide patient specific **insights on adherence** (obtained from remote monitoring devices), and what might cause **patients to skip drug regimens**.

As detailing calls of the Sales Representative will change, so will requirements of detailing materials, created by Marketing departments. We believe that detailing materials will be generated cloud based and in real-time during the call. Taking into account patient data and considering which information the HCP has already accessed/received via different channels such as Social Media and HCP platforms.

Around **patient data**, its ownership and security, a lot of **questions remain unanswered**. We believe that **Pharma companies** have to be **extremely aware** about **non-Pharma competitors pushing into the value chain** and securing valuable data. Consequently, Pharma companies have to be aware about not becoming the commodity provider. However, we believe that **Pharma companies are uniquely positioned to orchestrate the future collaboration between healthcare stakeholders** such as physicians, patients, payors, regulators and researchers focused around data. The Pharma industry is already well connected with stakeholders (e.g. for pricing discussions or research collaborations) and is highly experienced with the regulated environment it operates in.

Did we spark your interest? We would be pleased to exchange ideas!

**Dr. Götz Otto** Managing Partner Michael Mahnkopf Project Manager

OTTO & COMPANY is an independent strategy consultancy that offers its clients tailor-made solutions as well as continued support throughout implementations. In recent years, we have focused on both healthcare and financial services. Our offices in Munich, Madrid, Mexico City, Sao Paulo and Zurich enable us to offer support to our clients across the globe.

OTTO & COMPANY supports pharmaceutical companies to exploit the opportunities of digital transformation. Our experienced consultant team has proven expertise in the pharmaceutical industry as well as in digitalization projects across industries.

#### OTTO & COMPANY Strategy Consultants GmbH

Kardinal-Faulhaber-Str. 5, 80333 München http://www.otto-company.com